MARKER THERAPEUTICS, INC.: 10-Q filed 2011-11-21

Name: MARKER THERAPEUTICS, INC.: 10-Q filed 2011-11-21
Creator: MARKER THERAPEUTICS, INC.

What MARKER THERAPEUTICS, INC. reported in its quarterly report filed 2011-11-21 (fiscal Q3 2011): 18 published measures, 48 facts as tagged in accession 0001424884-11-000163.

This filing

Form: 10-Q (quarterly report)
Filed: 2011-11-21
Fiscal period: fiscal Q3 2011
Accession: 0001424884-11-000163 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-09-30	97,067	USD
At 2010-12-31	116,433	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2011-09-30	2,273,136	USD
At 2010-12-31	3,388,922	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2011-09-30	-2,176,069	USD
At 2010-12-31	-3,272,489	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	-844,277	USD	92
2011-01-01 to 2011-09-30	-2,378,036	USD	273
1999-07-27 to 2011-09-30	-45,879,801	USD	4449
2010-07-01 to 2010-09-30	-1,014,013	USD	92
2010-01-01 to 2010-09-30	-3,987,640	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	-1,010,910	USD	273
1999-07-27 to 2011-09-30	-14,849,480	USD	4449
2010-01-01 to 2010-09-30	-891,704	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
1999-07-27 to 2011-09-30	218,626	USD	4449

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	1,022,166	USD	273
1999-07-27 to 2011-09-30	14,679,505	USD	4449
2010-01-01 to 2010-09-30	895,014	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
1999-07-27 to 2011-09-30	204,747	USD	4449

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	1,052,513	USD	273
1999-07-27 to 2011-09-30	10,608,281	USD	4449
2010-01-01 to 2010-09-30	2,116,118	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	-904,931	USD	92
2011-01-01 to 2011-09-30	-2,706,726	USD	273
1999-07-27 to 2011-09-30	-34,371,892	USD	4449
2010-07-01 to 2010-09-30	-1,233,858	USD	92
2010-01-01 to 2010-09-30	-4,146,449	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-09-30	60,907	USD
At 2010-12-31	25,299	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-09-30	1,705,009	USD
At 2010-12-31	3,388,922	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	297,996	USD	92
2011-01-01 to 2011-09-30	406,944	USD	273
1999-07-27 to 2011-09-30	6,114,384	USD	4449
2010-07-01 to 2010-09-30	93,517	USD	92
2010-01-01 to 2010-09-30	243,380	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2011-09-30	47,360,721	shares
At 2010-12-31	40,256,027	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2011-09-30	-58,607	USD
At 2010-12-31	-60,895	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-07-01 to 2011-09-30	23,875	USD	92
2011-01-01 to 2011-09-30	66,012	USD	273
1999-07-27 to 2011-09-30	2,677,534	USD	4449
2010-07-01 to 2010-09-30	32,827	USD	92
2010-01-01 to 2010-09-30	142,870	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
1999-07-27 to 2011-09-30	213,227	USD	4449

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2011-01-01 to 2011-09-30	194,750	USD	273
1999-07-27 to 2011-09-30	9,816,875	USD	4449

Inspect the source

Entity: MARKER THERAPEUTICS, INC. / CIK 0001094038
Captured: 2026-09-20T05:22:11.393Z
SEC response SHA-256: 11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))